Friday, 14 February 2025
  
Login

Australia's most trusted
source of pharma news

Friday, 14 February 2025
News

$61M fall to generic competitors

Posted 4 February 2025 AM

Four PBS-listed drugs face generic competition for the first time in February, with first new brands being listed on drugs earning a collective $61.5 million in 2024.

AstraZeneca's heart drug Brilinta shifted to the F2 Formulary, with a 25 per cent drop in price, as two generic versions hit the PBS. In the calendar year 2024 Brilinta earned the pharma $28 million in pre-rebate R/PBS reimbursements, meaning a shave of $7 million a year.

To see the whole article, please login


Latest Jobs
Pharma in Focus  Jobs

Marketing & Communications (4)

Sales & Customer Relations (14)

Clinical & Medical, R&D (7)

Regulatory, Pharmacovigilance & QA (4)

Other (14)

MORE NEWS
Email this article to a friend
From:

 
 
  
Print this article

Copyright Notice

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.

Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.

Welcome to Pharma in Focus

Please log in to read.

Hi

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Hi

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

Hi

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

 

You can choose not to do this now but after November 30, a password will be required.

To learn more about the new-look Pharma in Focus click here.